This report describes a patient with extramedullary relapse of acute myeloid leukemia (AML) 
Introduction

Myeloid sarcoma (MS) is a tumor mass consisting of myeloid blasts with or without maturation occurring at an anatomical site other than the bone marrow (1). It is also known as chloroma, granulocytic sarcoma, or extramedullary tumor, and may precede or coincide with acute myeloid leukemia (AML) (2, 3). Rarely, it also occurs in AML without bone marrow relapse. We report a case of MS as a recurrence of AML without involving the bone marrow after achieving complete response (CR) with chemotherapy alone. Cytogenetic analysis with fluorescence in situ hybridization (FISH) was available at the relapse site and clonal evolution of the leukemic cells was observed.
Case Report
A 57-year-old man was admitted to our hospital in Octo (Fig. 3) . Aspiration cytology at the site disclosed infiltration of blastlike cells (Fig. 4A) . The cells were negative for peroxidase staining and positive for non-specific esterase staining ( Fig. 4B and 4C) . The cell surface marker analysis by flow cytometry showed that the cells were positive for CD4, CD 
13, CD16, CD33, CD56, and HLA-DR (Fig. 5). Thus, MS as extramedullary relapse of AML was diagnosed. Chromosomal analysis of the cells was not available because no di-
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. ( Fig. 6A) . FISH analysis also showed that 9% of the cells had three signals with chromosome 8 centromere probe and 70% of the cells had four signals (Fig. 6B and Fig. 6C) , suggesting that the majority of leukemic cells had tetrasomy 8. (8) (1-3, 9, 10) .
After admission, a gradually enlarging round hard mass of 5 cm in diameter in back of the right thigh emerged and the pain in the right lower extremity became agonizing. His neurological symptoms were considered to have been caused by extramedullary relapse of leukemic cells, possibly presenting as nerve root entrapment syndrome as previously reported (5). As the relapse was considered to be multifocal, we chose intravenous chemotherapy rather than local radiation therapy. We selected gemtuzumab ozogamicin (GO) because some promising results for MS had been reported (6, 7). The patient received two doses of GO at 9 mg/m 2 per dose, with a 14-day interval between doses. Though transient alleviation of the pain after GO administration could be obtained, no apparent regression of the tumors was observed. The pain worsened daily with gradual enlargement of the masses and the patient became cachectic. The patient and his family declined to receive high dose cytarabine therapy and a CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colonystimulating factor) regimen was started
Cases of intramuscular infiltration of MS as in our case
have also been reported, however, they were considered to be extremely rare (11, 12 
